Intermagnetics bids for Invivo

Article

In an effort to broaden its line of MR products, Intermagnetics General has launched a hostile bid for a developer of vital signs monitors. The Latham, NY-based company, best known in the imaging industry for supplying superconducting magnets to Philips

In an effort to broaden its line of MR products, Intermagnetics General has launched a hostile bid for a developer of vital signs monitors. The Latham, NY-based company, best known in the imaging industry for supplying superconducting magnets to Philips Medical Systems, has offered $140 million in cash and stock, $19 for each share of Invivo. The bid, which includes $15 cash per share, represents a 20% premium over the stock's 50-day moving average and 14% above the closing price of the stock Nov. 3, when the offer was publicly announced. Executives at Invivo, a market leader in patient monitors designed for use in the very high magnetic fields, have rebuffed previous overtures from Intermagnetics to discuss a buyout.

"We are disappointed that they have repeatedly failed to respond meaningfully to our overtures," said Glenn H. Epstein, chairman and CEO of Intermagnetics. "Because this is a transaction that provides Invivo's stockholders with an opportunity to realize immediate financial gain and liquidity, we believe we had no alternative but to make our proposal public."

Intermagnetics is attracted not only to Invivo's products, which would complement its own, but also to its diversified customer base. The company plans to leverage global sales and service channels that Invivo uses to sell monitors to boost its own MR coil business. Company executives estimate that the effect on earnings of a merger would be slightly accretive within the current fiscal year, ending May 2004, and substantially accretive during fiscal 2005 following a full year's contribution of earnings.

Recent Videos
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
Related Content
© 2025 MJH Life Sciences

All rights reserved.